Navigation Links
BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013

BOULDER, Colo., and SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- BiOptix in conjunction with Molecular Med TRI-CON 2013 will officially announce the expansion of the BiOptix Innovators Program, a unique-to-the-industry "try before you buy" instrument demo program that encourages researchers and institutions to become acquainted with the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology. 

During the event, Ken Wilczek , Vice President of Sales and Marketing for BiOptix remarked: "We are actively seeking and qualifying researchers and institutions who would like to experience a new way of evaluating and purchasing an SPR instrument."  "Through the marriage of excellent customer service and world-class technology, BiOptix aims to simplify the SPR instrument evaluation process, building a true partnership with scientific researchers to demonstrate the capabilities of the 404pi, a 21st century benchmark for new and innovative label-free SPR instrumentation."  "Quite simply, this is not your father's SPR instrument—the BiOptix 404pi will change how you think and work with SPR." continued Wilczek.  

Additional details about the BiOptix Innovators Program, including how you or your institution can request a demo of the BiOptix 404pi can be found at: or by contacting BiOptix at:  303-545-5550 x 125.

In addition to Molecular Med TRI-CON 2013, BiOptix will be highlighting the 404pi at the following events during the first half of 2013:

  • PepTalk 2013 – The Protein Science Week
  • BioPhysical Society 57th Annual Meeting
  • IBC's Biopharmaceutical Development & Production Week
  • AACR — The American Association for Cancer Research
  • 9th Annual Pegs — The Essential Protein Engineering Summit
  • 2013 Merck Technology Symposia
  • TIDES 2013 — Oligonucleotide and Peptide Research, Technology and Product Development
  • 2013 Bristol-Myers Squibb Vendor & Technology Symposia

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:

SOURCE BiOptix Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
2. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
3. OrbusNeich Announces Favorable Ruling From the European Patent Office
4. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
5. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
6. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
7. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
8. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
9. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
10. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
11. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
Post Your Comments:
(Date:11/27/2015)... , Niederlande, November 27, 2015 ... Bremachlorin-Therapie bei fortgeschrittenem Krebs.   --> ... bei fortgeschrittenem Krebs.   --> ... bei fortgeschrittenem Krebs.   Clinical Cancer ... --> Clinical Cancer Research vom 6. ...
(Date:11/27/2015)... Research and Markets ( ) has ... Market 2015-2019" report to their offering. ... report, the author the present scenario and growth prospects ... calculate the market size, the report considers revenue generated ... IUDs and copper IUDs. The report forecasts the global ...
(Date:11/26/2015)... PUNE, India , November ... --> ... / personal emergency response system ... grow steadily for 5 years ... growing region expected to see ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):